Loading...
•
Dec 31, 2021
Nektar Q4 2021 Earnings Report
Nektar's financial results for Q4 2021 were reported.
Key Takeaways
Nektar Therapeutics reported revenue of $25.0 million and a net loss of $145.6 million for the fourth quarter of 2021. The company's cash and investments in marketable securities were approximately $0.8 billion at the end of the year. Nektar is advancing its clinical pipeline in oncology, immunology, and virology.
Revenue for the fourth quarter of 2021 was $25.0 million, compared to $23.5 million in the fourth quarter of 2020.
Total operating costs and expenses in the fourth quarter of 2021 were $137.9 million, compared to $134.2 million in the fourth quarter of 2020.
R&D expense in the fourth quarter of 2021 was $99.6 million, compared to $102.7 million for the fourth quarter of 2020.
Net loss for the fourth quarter of 2021 was $145.6 million, or $0.79 basic and diluted loss per share, compared to a net loss of $117.2 million, or $0.65 basic and diluted loss per share in the fourth quarter of 2020.
Forward Guidance
Nektar expects topline results from three registrational trials evaluating bempegaldesleukin in combination with a checkpoint inhibitor in melanoma, renal cell carcinoma and bladder cancer in the first half of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...